drugset / Trial / NCT05994534

PK and PD Study of NPI-001 and Cysteamine Bitartrate

NCT05994534

Phase 1/2 Active not recruiting 12 enrolled Nacuity Pharmaceuticals, Inc.
Non-randomizedCrossoverOpen-labelTreatment

Summary

Safety, pharmacokinetics, and pharmacodynamics of NPI-001 oral solution in cystinosis patients compared with cysteamine.

Timeline

Start
2023-10-29
Primary completion
2026-08
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cysteamine Unknown
Subject N-Acetylcysteine Amide Unknown Oral

Indications